Table 2.
Sectorial analysis, case-control analysis and subgroup analysis showed no significant difference in 18F-labelled fluorodeoxyglucose uptake
| Mean SUVmax | Mean SUVmean | |
| Sectorial analysis | ||
| MRI - normal prostatic sectors | 3.02 | 1.74 |
| MRI - suspicious prostatic sectors | 3.1 | 1.89 |
| Histopathology - benign prostatic lobe | 2.86 | 1.79 |
| Histopathology - malignant prostatic lobe | 3.13 | 1.82 |
| Case-control analysis | ||
| Age-matched controls | 3.09 | 1.83 |
| Cases with prostate cancer | 3.26 | 1.81 |
| Subgroup analysis | ||
| Biopsy not performed | 4.95 | 1.91 |
| Benign disease and high-grade PIN | 5.85 | 2.86 |
| Low-grade prostate cancer (Gleason ≤ 3 + 4) | 3.2 | 1.83 |
| High-grade prostate cancer (Gleason score ≥ 4 + 3) | 3.35 | 1.78 |
SUV: Standardised uptake value, PIN: Prostatic intraepithelial neoplasia.